Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Automated segmentation of medial temporal lobe subregions on in vivo T1-weighted MRI in early stages of Alzheimer&apos, s disease

  • Xie, Long
  • Wisse, Laura E. M.
  • Pluta, John
  • de Flores, Robin
  • Piskin, Virgine
  • Wang, Hongzhi
  • Das, Sandhitsu R.
  • Ding, Song-Lin
  • Wolk, David A.
  • Yushkevich, Paul A.
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Medial temporal lobe (MTL) substructures are the earliest regions affected by neurofibrillary tangle pathology-and thus are promising biomarkers for Alzheimer's disease (AD). However, automatic segmentation of the MTL using only T1-weighted (T1w) magnetic resonance imaging (MRI) is challenging due to the large anatomical variability of the MTL cortex and the confound of the dura mater, which is commonly segmented as gray matter by state-of-the-art algorithms because they have similar intensity in T1w MRI. To address these challenges, we developed a novel atlas set, consisting of 15 cognitively normal older adults and 14 patients with mild cognitive impairment with a label explicitly assigned to the dura, that can be used by the multiatlas automated pipeline (Automatic Segmentation of Hippocampal Subfields [ASHS-T1]) for the segmentation of MTL subregions, including anterior/posterior hippocampus, entorhinal cortex (ERC), Brodmann areas (BA) 35 and 36, and parahippocampal cortex on T1w MRI. Cross-validation experiments indicated good segmentation accuracy of ASHS-T1 and that the dura can be reliably separated from the cortex (6.5% mislabeled as gray matter). Conversely, FreeSurfer segmented majority of the dura mater (62.4%) as gray matter and the degree of dura mislabeling decreased with increasing disease severity. To evaluate its clinical utility, we applied the pipeline to T1w images of 663 ADNI subjects and significant volume/thickness loss is observed in BA35, ERC, and posterior hippocampus in early prodromal AD and all subregions at later stages. As such, the publicly available new atlas and ASHS-T1 could have important utility in the early diagnosis and monitoring of AD and enhancing brain-behavior studies of these regions., Northern California Institute for Research and Education; Foundation for the National Institutes of Health; Canadian Institutes of Health Research; Transition Therapeutics; Takeda Pharmaceutical Company; Servier; Piramal Imaging; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Neurotrack Technologies; NeuroRx Research; Meso Scale Diagnostics, LLC.; Lundbeck and Merck & Co., Inc.; Lumosity; Johnson & Johnson Pharmaceutical Research & Development LLC.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; IXICO Ltd.; GE Healthcare; Fujirebio; Genentech, Inc.; F. Hoffmann-La Roche Ltd.; EuroImmun; Eli Lilly and Company; Elan Pharmaceuticals, Inc.; Cogstate and Eisai Inc.; CereSpir, Inc.; Bristol-Myers Squibb Company; Biogen; BioClinica, Inc.; Araclon Biotech; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; AbbVie; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; Department of Defense ADNI, Grant/Award Number: W81XWH-12-2-0012; Alzheimer's Disease Neuroimaging Initiative, Grant/Award Number: U01 AG024904; Spain Ministry of Economy, Industry and Competitiveness, Grant/Award Number: DPI2017-87743-R; Foundation Philippe Chatrier; BrightFocus Foundation; National Institutes of Health, Grant/Award Numbers: R01-AG055005, R01-EB017255, P30-AG010124, R01-AG040271, R01-AG056014
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Lifespan Changes of the Human Brain In Alzheimer&apos, s Disease

  • Coupé, Pierrick
  • Lanuza, Enrique
  • Catheline, Gwenaelle
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Brain imaging studies have shown that slow and progressive cerebral atrophy characterized the development of Alzheimer's Disease (AD). Despite a large number of studies dedicated to AD, key questions about the lifespan evolution of AD biomarkers remain open. When does the AD model diverge from the normal aging model? What is the lifespan trajectory of imaging biomarkers for AD? How do the trajectories of biomarkers in AD differ from normal aging? To answer these questions, we proposed an innovative way by inferring brain structure model across the entire lifespan using a massive number of MRI (N = 4329). We compared the normal model based on 2944 control subjects with the pathological model based on 3262 patients (AD + Mild cognitive Impaired subjects) older than 55 years and controls younger than 55 years. Our study provides evidences of early divergence of the AD models from the normal aging trajectory before 40 years for the hippocampus, followed by the lateral ventricles and the amygdala around 40 years. Moreover, our lifespan model reveals the evolution of these biomarkers and suggests close abnormality evolution for the hippocampus and the amygdala, whereas trajectory of ventricular enlargement appears to follow an inverted U-shape. Finally, our models indicate that medial temporal lobe atrophy and ventricular enlargement are two mid-life physiopathological events characterizing AD brain., This work benefited from the support of the project DeepVolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX- 03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS. This study has been also supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria y Competitividad. Moreover, this work is based on multiple samples. We wish to thank all investigators of these projects who collected these datasets and made them freely accessible. The C-MIND data used in the preparation of this article were obtained from the C-MIND Data Repository (accessed in Feb 2015) created by the C-MIND study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by Cincinnati Children's Hospital Medical Center and UCLA and supported by the National Institute of Child Health and Human Development (Contract #s HHSN275200900018C). A listing of the participating sites and a complete listing of the study investigators can be found at https://research.cchmc.org/c-mind. The NDAR data used in the preparation of this manuscript were obtained from the NIH-supported National Database for Autism Research (NDAR). NDAR is a collaborative informatics system created by the National Institutes of Health to provide a national resource to support and accelerate research in autism. The NDAR dataset includes data from the NIH Pediatric MRI Data Repository created by the NIH MRI Study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://pediatricmri.nih.gov/nihpd/info/participating_centers.html. The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

BEaST: Brain extraction based on nonlocal segmentation technique

  • Eskildsen, Simon F.
  • Coupé, Pierrick
  • Fonov, Vladimir
  • Leung, Kelvin K.
  • Guizard, Nicolas
  • Wassef, Shafik N.
  • Østergaard, Lasse Riis
  • Collins, D. Louis
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Alzheimer's Dis Neuroimaging
Brain extraction is an important step in the analysis of brain images. The variability in brain morphology and the difference in intensity characteristics due to imaging sequences make the development of a general purpose brain extraction algorithm challenging. To address this issue, we propose a new robust method (BEaST) dedicated to produce consistent and accurate brain extraction. This method is based on nonlocal segmentation embedded in a multi-resolution framework. A library of 80 priors is semi-automatically constructed from the NIH-sponsored MRI study of normal brain development, the International Consortium for Brain Mapping, and the Alzheimer's Disease Neuroimaging Initiative databases. In testing, a mean Dice similarity coefficient of 0.9834 ± 0.0053 was obtained when performing leave-one-out cross validation selecting only 20 priors from the library. Validation using the online Segmentation Validation Engine resulted in a top ranking position with a mean Dice coefficient of 0.9781 ± 0.0047. Robustness of BEaST is demonstrated on all baseline ADNI data, resulting in a very low failure rate. The segmentation accuracy of the method is better than two widely used publicly available methods and recent state-of-the-art hybrid approaches. BEaST provides results comparable to a recent label fusion approach, while being 40 times faster and requiring a much smaller library of priors., Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514, and the Dana Foundation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Artificial Intelligence on FDG PET Images Identifies Mild Cognitive Impairment Patients with Neurodegenerative Disease

  • Prats-Climent, Joan|||0000-0002-9775-4671
  • Rodríguez-Álvarez, M.J.|||0000-0001-8333-8792
  • Gandia-Ferrero, Maria Teresa
  • Torres-Espallardo, Irene
  • Álvarez-Sanchez, Lourdes
  • Martinez-Sanchis, Begoña
  • Cháfer-Pericás, Consuelo
  • Gómez-Rico, Ignacio
  • Cerdá-Alberich, Leonor
  • Aparici-Robles, Fernando
  • Baquero-Toledo, Miquel
  • Marti-Bonmati, Luis
[EN] The purpose of this project is to develop and validate a Deep Learning (DL) FDG PET imaging algorithm able to identify patients with any neurodegenerative diseases (Alzheimer's Disease (AD), Frontotemporal Degeneration (FTD) or Dementia with Lewy Bodies (DLB)) among patients with Mild Cognitive Impairment (MCI). A 3D Convolutional neural network was trained using images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The ADNI dataset used for the model training and testing consisted of 822 subjects (472 AD and 350 MCI). The validation was performed on an independent dataset from La Fe University and Polytechnic Hospital. This dataset contained 90 subjects with MCI, 71 of them developed a neurodegenerative disease (64 AD, 4 FTD and 3 DLB) while 19 did not associate any neurodegenerative disease. The model had 79% accuracy, 88% sensitivity and 71% specificity in the identification of patients with neurodegenerative diseases tested on the 10% ADNI dataset, achieving an area under the receiver operating characteristic curve (AUC) of 0.90. On the external validation, the model preserved 80% balanced accuracy, 75% sensitivity, 84% specificity and 0.86 AUC. This binary classifier model based on FDG PET images allows the early prediction of neurodegenerative diseases in MCI patients in standard clinical settings with an overall 80% classification balanced accuracy., This work was financially supported by INBIO 2019 (DEEPBRAIN), INNVA1/2020/83(DEEPPET) funded by Generalitat Valenciana, and PID2019-107790RB-C22 funded by MCIN/AEI/10.13039/501100011033/. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Hippocampal-amygdalo-ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models

  • Coupé, Pierrick
  • Mansencal, Boris
  • Tourdias, Thomas
  • Catheline, Gwenaelle
  • Planche, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] In this article, we present an innovative MRI-based method for Alzheimer disease (AD) detection and mild cognitive impairment (MCI) prognostic, using lifespan trajectories of brain structures. After a full screening of the most discriminant structures between AD and normal aging based on MRI volumetric analysis of 3,032 subjects, we propose a novel Hippocampal-Amygdalo-Ventricular Atrophy score (HAVAs) based on normative lifespan models and AD lifespan models. During a validation on three external datasets on 1,039 subjects, our approach showed very accurate detection (AUC >= 94%) of patients with AD compared to control subjects and accurate discrimination (AUC = 78%) between progressive MCI and stable MCI (during a 3-year follow-up). Compared to normative modeling, classical machine learning methods and recent state-of-the-art deep learning methods, our method demonstrated better classification performance. Moreover, HAVAs simplicity makes it fully understandable and thus well-suited for clinical practice or future pharmaceutical trials., UK Alzheimer's Society, Grant/Award Number: RF116; GlaxoSmithKline, Grant/Award Number: 6GKC; Leon Levy Foundation; NIMH, Grant/Award Numbers: R03MH096321, K23MH087770; ABIDE; U.K. Engineering and Physical Sciences Research Council, Grant/Award Number: GR/S21533/02; Canadian Institutes of Health Research, Grant/Award Number: MOP-34996; Human Brain Project, Grant/Award Number: PO1MHO52176-11; Alzheimer Drug Discovery Foundation; Alzheimer Association; National Health and Medical Research Council of Australia, Grant/Award Number: 1011689; Science Industry Endowment Fund; Common-wealth Scientific Industrial Research Organization; OASIS Brains Datasets, Grant/Award Numbers: P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584; NIH, Grant/Award Numbers: K01 AG030514, P30AG010129; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; National Institutes of Health, Grant/Award Number: U01 AG024904; National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Institute on Drug Abuse; National Institute of Child Health and Human Development, Grant/Award Number: HHSN275200900018C; Ministerio de Ciencia e Innovacion, Grant/Award Number: PID2020-118608RB-I00; French National Research Agency, Grant/Award Number: ANR-18-CE45-0013
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

An Optimized PatchMatch for multi-scale and multi-feature label fusion

  • Giraud, Rémi
  • Ta, Vinh-Thong
  • Papadakis, Nicolas
  • Collins, Louis
  • Coupé Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Alzheimers Dis Neuroimaging Initia
Automatic segmentation methods are important tools for quantitative analysis of Magnetic Resonance Images (MRI). Recently, patch-based label fusion approaches have demonstrated state-of-the-art segmentation accuracy. In this paper, we introduce a new patch-based label fusion framework to perform segmentation of anatomical structures. The proposed approach uses an Optimized PAtchMatch Label fusion (OPAL) strategy that drastically reduces the computation time required for the search of similar patches. The reduced computation time of OPAL opens the way for new strategies and facilitates processing on large databases. In this paper, we investigate new perspectives offered by OPAL, by introducing a new multi-scale and multi-feature framework. During our validation on hippocampus segmentation we use two datasets: young adults in the ICBM cohort and elderly adults in the EADC-ADNI dataset. For both, OPAL is compared to state-of-the-art methods. Results show that OPAL obtained the highest median Dice coefficient (89.9% for ICBM and 90.1% for EADC-ADNI). Moreover, in both cases, OPAL produced a segmentation accuracy similar to inter-expert variability. On the EADC-ADNI dataset, we compare the hippocampal volumes obtained by manual and automatic segmentation. The volumes appear to be highly correlated that enables to perform more accurate separation of pathological populations. (C) 2015 Elsevier Inc. All rights reserved., This study has been carried out with financial support from the French State, managed by the French National Research Agency (ANR) in the frame of the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02), Cluster of excellence CPU and TRAIL (HR-DTI ANR-10-LABX-57). We also thank Tong Tong and Daniel Rueckert for providing us complete results of the methods proposed in Tong et al. (2013), Sonia Tangaro and Marina Boccardi for providing us complete results of the method proposed in Tangaro et al. (2014), and Katherine Gray and Robin Wolz for providing us complete results of the LEAP method proposed in Gray et al. (2014). Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by the Spanish grant TIN2013-43457-R from the Ministerio de Economia y competitividad, NIH grants P30AG010129, K01 AG030514 and the Dana Foundation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Towards a Unified Analysis of Brain Maturation and Aging across the Entire Lifespan: A MRI Analysis

  • Coupé, Pierrick
  • Catheline, Gwenaelle
  • Lanuza, Enrique
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] There is no consensus in literature about lifespan brain maturation and senescence, mainly because previous lifespan studies have been performed on restricted age periods and/or with a limited number of scans, making results instable and their comparison very difficult. Moreover, the use of nonharmonized tools and different volumetric measurements lead to a great discrepancy in reported results. Thanks to the new paradigm of BigData sharing in neuroimaging and the last advances in image processing enabling to process baby as well as elderly scans with the same tool, new insights on brain maturation and aging can be obtained. This study presents brain volume trajectory over the entire lifespan using the largest age range to date (from few months of life to elderly) and one of the largest number of subjects (N=2,944). First, we found that white matter trajectory based on absolute and normalized volumes follows an inverted U-shape with a maturation peak around middle life. Second, we found that from 1 to 8-10 y there is an absolute gray matter (GM) increase related to body growth followed by a GM decrease. However, when normalized volumes were considered, GM continuously decreases all along the life. Finally, we found that this observation holds for almost all the considered subcortical structures except for amygdala which is rather stable and hippocampus which exhibits an inverted U-shape with a longer maturation period. By revealing the entire brain trajectory picture, a consensus can be drawn since most of the previously discussed discrepancies can be explained. Hum Brain Mapp 38:5501-5518, 2017. (C) 2017 Wiley Periodicals, Inc., French State (French National Research Ageny in the frame of the Investments for the future Program IdEx Bordeaux); Contract grant number: ANR-10-IDEX-03-02, HL-MRI Project; Contract grant sponsor: Cluster of excellence CPU and TRAIL (HR-DTI ANR-10-LABX-57); Contract grant sponsor: CNRS ("Defi imag'In and the dedicated volBrain support); Contract grant sponsor: Ministerio de Economia y competitividad (Spanish); Contract grant number: TIN2013-43457-R; Contract grant sponsor: National Institute of Child Health and Human Development; Contract grant number: HHSN275200900018C; Contract grant sponsors: National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke; Contract grant numbers: N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320; Contract grant sponsor: National Institutes of Health; Contract grant number: U01 AG024904; Contract grant sponsor: National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering (ADNI); Contract grant sponsor: NIH; Contract grant number: P30AG010129, K01 AG030514; Contract grant sponsor: Dana Foundation; Contract grant sponsor: OASIS project (OASIS data); Contract grant numbers: P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584; Contract grant sponsor: Common-wealth Scientific Industrial Research Organization (a publicly funded government research organization); Contract grant sponsor: Science Industry Endowment Fund, National Health and Medical Research Council of Australia; Contract grant number: 1011689; Contract grant sponsors: Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and an anonymous foundation; Contract grant sponsor: Human Brain Project; Contract grant number: PO1MHO52176-11 (ICBM, P.I. Dr John Mazziotta); Contract grant sponsor: Canadian Institutes of Health Research; Contract grant number: MOP-34996; Contract grant sponsor: U.K. Engineering and Physical Sciences Research Council (EPSRC); Contract grant number: GR/S21533/02; Contract grant sponsor: ABIDE funding resources; Contract grant sponsor: NIMH; Contract grant number: K23MH087770; Contract grant sponsor: Leon Levy Foundation; Contract grant sponsor: NIMH award to MPM; Contract grant number: R03MH096321
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Structural connectivity centrality changes mark the path towards Alzheimer&apos, s disease

  • Peraza, Luis R.
  • Díaz-Parra, Antonio
  • Kennion, Oliver
  • Taylor, John-Paul
  • Kaiser, Marcus
  • Bauer, Roman
  • Moratal, David|||0000-0002-2825-3646
[EN] Introduction: The pathophysiological process of Alzheimer's disease is thought to begin years before clinical decline, with evidence suggesting prion-like spreading processes of neurofibrillary tangles and amyloid plaques. Methods: Using diffusion magnetic resonance imaging data from the Alzheimer's Disease Neuroimaging Initiative database, we first identified relevant features for dementia diagnosis. We then created dynamic models with the Nathan Kline Institute-Rockland Sample database to estimate the earliest detectable stage associated with dementia in the simulated disease progression. Results: A classifier based on centrality measures provides informative predictions. Strength and closeness centralities are the most discriminative features, which are associated with the medial temporal lobe and subcortical regions, together with posterior and occipital brain regions. Our model simulations suggest that changes associated with dementia begin to manifest structurally at early stages. Discussion: Our analyses suggest that diffusion magnetic resonance imaging-based centrality measures can offer a tool for early disease detection before clinical dementia onset., The authors would like to thank Peter N. Taylor and Yujiang Wang for their stimulating feedback and suggestions. Funding: A.D.-P. was supported by grant FPU13/01475 from the Spanish Ministerio de Educacion, Cultura y Deporte (MECD). This work was supported in part by the Spanish Ministerio de Economıa y Competitividad (MINECO) and FEDER funds under grant BFU2015- 64380-C2-2-R. L.R.P. and J.-P.T. were supported by the NIHR Newcastle Biomedical Research Center awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. M.K. and R.B. were supported by the Engineering and Physical Sciences Research Council of the United Kingdom (EP/K026992/1). R.B. was also supported by (EP/S001433/1) and the Medical Research Council of the United Kingdom (MR/N015037/1). Data collection and sharing for this project was funded by the Alzheimer s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2- 0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and generous contributions from the following organizations: AbbVie, Alzheimer s Association; Alzheimer s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

AssemblyNet: A large ensemble of CNNs for 3D whole brain MRI segmentation

  • Coupé, Pierrick
  • Mansencal, Boris
  • Clement, Michael
  • Giraud, Rémi
  • Denis de Senneville, Baudouin
  • Ta, Vinh-Thong
  • Lepetit, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Whole brain segmentation of fine-grained structures using deep learning (DL) is a very challenging task since the number of anatomical labels is very high compared to the number of available training images. To address this problem, previous DL methods proposed to use a single convolution neural network (CNN) or few independent CNNs. In this paper, we present a novel ensemble method based on a large number of CNNs processing different overlapping brain areas. Inspired by parliamentary decision-making systems, we propose a framework called AssemblyNet, made of two "assemblies" of U-Nets. Such a parliamentary system is capable of dealing with complex decisions, unseen problem and reaching a relevant consensus. AssemblyNet introduces sharing of knowledge among neighboring U-Nets, an "amendment" procedure made by the second assembly at higher-resolution to refine the decision taken by the first one, and a final decision obtained by majority voting. During our validation, AssemblyNet showed competitive performance compared to state-of-the-art methods such as U-Net, Joint label fusion and SLANT. Moreover, we investigated the scan-rescan consistency and the robustness to disease effects of our method. These experiences demonstrated the reliability of AssemblyNet. Finally, we showed the interest of using semi-supervised learning to improve the performance of our method., This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-0 3-02, HL-MRI Project), Cluster of excellence CPU and the CNRS/INSERM for the DeepMultiBrain project. This study has been also supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria Competitividad. The C-MIND data used in the preparation of this article were obtained from the C-MIND Data Repository (accessed in Feb 2015) created by the C-MIND study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by Cincinnati Children's Hospital Medical Center and UCLA and supported by the National Institute of Child Health and Human Development (Contract #s HHSN275200900018C). The NDAR data used in the preparation of this manuscript were obtained from the NIH-supported National Database for Autism Research (NDAR). This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://pediatricmri.nih.gov/nihpd/info/participating_centers.html. The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation. The OASIS data used in the preparation of this manuscript were obtained from the OASIS project funded by grants P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584. The AIBL data used in the preparation of this manuscript were obtained from the AIBL study of ageing funded by the Common-wealth Scientific Industrial Research Organization (CSIRO; a publicly funded government research organization), Science Industry Endowment Fund, National Health and Medical Research Council of Australia (project grant 1011689), Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and an anonymous foundation. The ICBM data used in the preparation of this manuscript were supported by Human Brain Project grant PO1MHO52176-11 (ICBM, P.I. Dr John Mazziotta) and Canadian Institutes of Health Research grant MOP-34996. The IXI data used in the preparation of this manuscript were supported by the U.K. Engineering and Physical Sciences Research Council (EPSRC) GR/S21533/02. ABIDE primary support for the work by Adriana Di Martino was provided by the NIMH (K23MH087770) and the Leon Levy Foundation. Primary support for the work by Michael P. Milham and the INDI team was provided by gifts from Joseph P. Healy and the Stavros Niarchos Foundation to the Child Mind Institute, as well as by an NIMH award to MPM (R03MH096321).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Scoring by nonlocal image patch estimator for early detection of Alzheimer&apos, s disease

  • Coupé, Pierrick
  • Eskildsen, Simon F.
  • Fonov, Vladirmir S.
  • Pruessner, Jens C.
  • Allard, Michèle
  • Collins, Louis D.
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
Detection of Alzheimer's disease (AD) at the first stages of the pathology is an important task to accelerate the development of new therapies and improve treatment. Compared to AD detection, the prediction of AD using structural MRI at the mild cognitive impairment (MCI) or pre-MCI stage is more complex because the associated anatomical changes are more subtle. In this study, we analyzed the capability of a recently proposed method, SNIPE (Scoring by Nonlocal Image Patch Estimator), to predict AD by analyzing entorhinal cortex (EC) and hippocampus (HC) scoring over the entire ADNI database (834 scans). Detection (AD vs. CN) and prediction (progressive - pMCI vs. stable - sMCI) efficiency of SNIPE were studied using volumetric and grading biomarkers. First, our results indicate that grading-based biomarkers are more relevant for prediction than volume-based biomarkers. Second, we show that HC-based biomarkers are more important than EC-based biomarkers for prediction. Third, we demonstrate that the results obtained by SNIPE are similar to or better than results obtained in an independent study using HC volume, cortical thickness, and tensor-based morphometry, individually and in combination. Fourth, a comparison of new patch-based methods shows that the nonlocal redundancy strategy involved in SNIPE obtained similar results to a new local sparse-based approach. Finally, we present the first results of patch-based morphometry to illustrate the progression of the pathology., We wish to thank Dr. Robin Wolz for providing the list of ADNI subjects used in his study, which allowed us to perform the presented method comparison. We also want to thank the Canadian Institutes of Health Research (MOP-111169) and the Fonds de la recherche en sante du Quebec. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U. S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation and also by the Spanish grant TIN2011-26727 from the Ministerio de Ciencia e Innovacion.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Multi-scale graph-based grading for Alzheimer&apos, s disease prediction

  • Hett, Kilian
  • Ta, Vinh-Thong
  • Oguz, Ipek
  • Coupé, Pierrick
  • Alzheimers Disease Neuroimaging Initiative
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] The prediction of subjects with mild cognitive impairment (MCI) who will progress to Alzheimer¿s disease (AD) is clinically relevant, and may above all have a significant impact on accelerating the development of new treatments. In this paper, we present a new MRI-based biomarker that enables us to accurately predict conversion of MCI subjects to AD. In order to better capture the AD signature, we introduce two main contributions. First, we present a new graph-based grading framework to combine inter-subject similarity features and intra-subject variability features. This framework involves patch-based grading of anatomical structures and graph-based modeling of structure alteration relationships. Second, we propose an innovative multiscale brain analysis to capture alterations caused by AD at different anatomical levels. Based on a cascade of classifiers, this multiscale approach enables the analysis of alterations of whole brain structures and hippocampus subfields at the same time. During our experiments using the ADNI-1 dataset, the proposed multiscale graph-based grading method obtained an area under the curve (AUC) of 81% to predict conversion of MCI subjects to AD within three years. Moreover, when combined with cognitive scores, the proposed method obtained 85% of AUC. These results are competitive in comparison to state-of-the-art methods evaluated on the same dataset., This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE450013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS. Finally, this work was also supported by the NIH grants R01-NS094456 and U01-NS106845. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01-AG024904) and by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Biogen; Bristol-Myes Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffman-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Pharmaceutical Research & Development LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute of Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

ALTEA: A Software Tool for the Evaluation of New Biomarkers for Alzheimer s Disease by Means of Textures Analysis on Magnetic Resonance Images

  • López-Gómez,Carlos
  • Ortiz-Ramón, Rafael
  • Mollá, Enrique
  • Moratal, David|||0000-0002-2825-3646
[EN] The current criteria for diagnosing Alzheimer's disease (AD) require the presence of relevant cognitive deficits, so the underlying neuropathological damage is important by the time the diagnosis is made. Therefore, the evaluation of new biomarkers to detect AD in its early stages has become one of the main research focuses. The purpose of the present study was to evaluate a set of texture parameters as potential biomarkers of the disease. To this end, the ALTEA (ALzheimer TExture Analyzer) software tool was created to perform 2D and 3D texture analysis on magnetic resonance images. This intuitive tool was used to analyze textures of circular and spherical regions situated in the right and left hippocampi of a cohort of 105 patients: 35 AD patients, 35 patients with early mild cognitive impairment (EMCI) and 35 cognitively normal (CN) subjects. A total of 25 statistical texture parameters derived from the histogram, the Gray-Level Co-occurrence Matrix and the Gray-Level Run-Length Matrix, were extracted from each region and analyzed statistically to study their predictive capacity. Several textural parameters were statistically significant (p < 0.05) when differentiating AD subjects from CN and EMCI patients, which indicates that texture analysis could help to identify the presence of AD., This work was supported in part by the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds under grant BFU2015-64380-C2-2-R. R.O.-R. was supported by grant ACIF/2015/078 from the Conselleria d'Educacio, Investigacio, Cultura i Esport of the Valencian Community (Spain).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Multimodal Hippocampal Subfield Grading For Alzheimer&apos, s Disease Classification

  • Hett, Kilian
  • Ta, Vinh-Thong
  • Catheline, Gwenaelle
  • Tourdias, Thomas
  • Coupé, Pierrick
  • Alzheimers Disease Neuroimaging Initiative
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Numerous studies have proposed biomarkers based on magnetic resonance imaging (MRI) to detect and predict the risk of evolution toward Alzheimer's disease (AD). Most of these methods have focused on the hippocampus, which is known to be one of the earliest structures impacted by the disease. To date, patch-based grading approaches provide among the best biomarkers based on the hippocampus. However, this structure is complex and is divided into different subfields, not equally impacted by AD. Former in-vivo imaging studies mainly investigated structural alterations of these subfields using volumetric measurements and microstructural modifications with mean diffusivity measurements. The aim of our work is to improve the current classification performances based on the hippocampus with a new multimodal patch-based framework combining structural and diffusivity MRI. The combination of these two MRI modalities enables the capture of subtle structural and microstructural alterations. Moreover, we propose to study the efficiency of this new framework applied to the hippocampal subfields. To this end, we compare the classification accuracy provided by the different hippocampal subfields using volume, mean diffusivity, and our novel multimodal patch-based grading framework combining structural and diffusion MRI. The experiments conducted in this work show that our new multimodal patch-based method applied to the whole hippocampus provides the most discriminating biomarker for advanced AD detection while our new framework applied into subiculum obtains the best results for AD prediction, improving by two percentage points the accuracy compared to the whole hippocampus., This study has been carried out with financial support from the French State, managed by the French National Research Agency (ANR) thanks to the funding of the project DeepvolBrain (ANR-18-CE45-0013) and in the frame of the Investments for the future Program IdEx Bordeaux, Cluster of excellence CPU and labex TRAIL (BigDataBrain ANR-10-LABX-57). The study presented in this work is a part of the thesis entitled "Multi-scale and multimodal imaging biomarkers for the early detection of Alzheimer's disease" defended by the same author. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Biogen; Bristol-Myes Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffman-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Pharmaceutical Research & Development LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute of Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.